Deeptech factory

DETERA THERAPEUTICS

Transformative Therapies for Rare Kidney Diseases

Our lead drug candidate DTR8 is a First-In-Class Disease-Modifying Drug for the treatment of crescentic glomerulonephritis, a severe condition with a high rate of therapeutic failure.

CEO : Lyse Santoro

Creation : october 2024

Headcount : 3

Location : Paris

Market(s) : Healthcare / Medtech

www.detera-therapeutics.com

#CrescenticGlomerulonephritis #RareKidneyDisease

TECHNO / PRODUITS

DTR8 is a peptide antagonist of HB-EGF.

PRODUCT PORTFOLIO

  • DTR8

APPLICATIONS

Treatment of crescentic glomerulonephritis at onset and relapse.

ADVANTAGES

  • Aims to protect glomeruli
  • Preserve renal function
  • Prevent progression to dialysis